DZ Bank Upgrades Astrazeneca (NYSE:AZN) to Buy

Key Points

• DZ Bank upgraded AstraZeneca from "neutral" to "buy" in a research note issued Wednesday, reflecting growing analyst optimism.
• AstraZeneca beat Q1 expectations, reporting EPS of $2.58 vs. $2.53 est and revenue of $15.29B vs. $14.74B, while reconfirming full‑year 2026 guidance.
• The company is investing in growth and its pipeline, exercising an option to license Pinetree’s EGFR degrader (PTX‑299) with a $25M payment and announcing a £300M (~$405M) investment in UK manufacturing sites.

Astrazeneca (NYSE:AZN - Get Free Report) was upgraded by DZ Bank from a "neutral" rating to a "buy" rating in a research note issued to investors on Wednesday,MarketScreener reports.

Several other research firms have also recently commented on AZN. Wall Street Zen cut Astrazeneca from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Weiss Ratings assumed coverage on Astrazeneca in a report on Wednesday, March 11th. They issued a "buy (b)" rating on the stock. Barclays reissued an "overweight" rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Astrazeneca in a report on Friday, February 6th. Finally, TD Cowen restated a "buy" rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $102.67.

Astrazeneca Price Performance

Shares of NYSE:AZN traded up $3.04 during midday trading on Wednesday, hitting $188.24. The company had a trading volume of 984,353 shares, compared to its average volume of 2,761,857. Astrazeneca has a twelve month low of $132.32 and a twelve month high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. The stock has a market cap of $291.94 billion, a PE ratio of 32.28, a P/E/G ratio of 1.42 and a beta of 0.35.

Astrazeneca (NYSE:AZN - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Astrazeneca had a return on equity of 31.57% and a net margin of 17.41%.The firm had revenue of $15.29 billion during the quarter, compared to analysts' expectations of $14.74 billion. Equities research analysts expect that Astrazeneca will post 10.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrazeneca

Hedge funds have recently bought and sold shares of the company. MV Capital Management Inc. acquired a new stake in Astrazeneca in the fourth quarter worth $26,000. Reflection Asset Management acquired a new position in Astrazeneca during the 4th quarter worth approximately $31,000. Raleigh Capital Management Inc. acquired a new stake in shares of Astrazeneca during the first quarter worth $38,000. Lloyd Advisory Services LLC. acquired a new stake in shares of Astrazeneca during the fourth quarter worth $35,000. Finally, Basepoint Wealth LLC bought a new position in shares of Astrazeneca during the fourth quarter valued at about $44,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca beat Q1 expectations — EPS $2.58 vs. $2.53 est and revenue $15.29B vs. $14.74B, while reconfirming full‑year 2026 guidance; management cited strong oncology and rare‑disease performance as drivers. AstraZeneca beats profit expectations, keeps annual outlook unchanged — Reuters
• Positive Sentiment: Citi raised its 2026 core EPS forecast for AZN to $10.30 (up ~2%) and reiterated a Buy rating, citing the Q1 beat and attractive risk/reward into second‑half pipeline readouts that the market may not have fully priced. Citi raises AstraZeneca earnings forecast and maintains 'buy' rating — Proactive
• Positive Sentiment: AstraZeneca exercised its option to license Pinetree’s EGFR degrader program (PTX‑299); the deal triggers a $25M option payment and gives AZN an exclusive global license to develop a first‑in‑class candidate — a near‑term non‑dilutive spend with potential pipeline upside. Pinetree announces exercise of option to license EGFR degrader — PR Newswire
• Positive Sentiment: UK investment: AstraZeneca will invest £300M (~$405M) in British sites, a move highlighted by UK leadership that supports long‑term manufacturing capacity and political/regulatory goodwill in its home market. AstraZeneca to make $405 million investment in Britain — Reuters
• Neutral Sentiment: Erste Group trimmed its FY2026 EPS estimate for AZN to $10.30 from $10.44 — a modest cut that broadly tracks consensus near ~$10.27 and appears to reflect fine‑tuning rather than a structural downgrade.
• Neutral Sentiment: Astra and Amgen are participating in FDA pilot work on “real‑time” trials using AI to speed development — strategically positive long‑term but unlikely to move near‑term revenue/earnings materially. Amgen, Astra launch real-time trials as FDA pilot — Seeking Alpha

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.